These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 10343036

  • 21. Drug marketing exclusivity under United States and European Union law.
    Junod V.
    Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Botanical drugs: a future for herbal medicines.
    Li W.
    J Contemp Health Law Policy; 2002; 19(1):117-49. PubMed ID: 12733224
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Control of manufacture--the EC point of view.
    Meyer P.
    Dev Biol Stand; 1992; 79():159-62. PubMed ID: 1286750
    [No Abstract] [Full Text] [Related]

  • 26. EC/FDA joint inspections.
    Nasto B.
    Nat Biotechnol; 2008 Aug; 26(8):847. PubMed ID: 18688225
    [No Abstract] [Full Text] [Related]

  • 27. Report on the PQRI impurity characterization and quantification best practices survey.
    Faustino P, Chan CC, Carrano J, Gosnell M, Gu ZQ, Maule A, Sigvardson K, Zhang YF.
    Pharm Res; 2006 Feb; 23(2):440-6. PubMed ID: 16477396
    [No Abstract] [Full Text] [Related]

  • 28. Regulators scramble to tighten loopholes after heparin debacle.
    Jia H.
    Nat Biotechnol; 2008 May; 26(5):477-8. PubMed ID: 18464756
    [No Abstract] [Full Text] [Related]

  • 29. Manufacturing misdeeds cost Abbott record-breaking payment.
    Lewis C.
    FDA Consum; 2000 May; 34(3):38-9. PubMed ID: 11521253
    [No Abstract] [Full Text] [Related]

  • 30. Preserving public confidence.
    Lancet Oncol; 2008 Jun; 9(6):503. PubMed ID: 18510980
    [No Abstract] [Full Text] [Related]

  • 31. Regulatory evaluation of biotechnology drugs: current trends in the United States.
    Sobel S.
    Bioprocess Technol; 1991 Jun; 13():499-511. PubMed ID: 1367148
    [No Abstract] [Full Text] [Related]

  • 32. [Demonstration of quality, safety and efficacy of biological products subject to changes in their manufacturing process].
    Vasil'ev AN, Gavrishina EV, Niiazov RR, Snegireva AA, Adonin VK.
    Antibiot Khimioter; 2013 Jun; 58(9-10):45-55. PubMed ID: 24738243
    [Abstract] [Full Text] [Related]

  • 33. Pitfalls of drug manufacturing--an evaluation of 18 months of FDA recalls.
    Frediani HA.
    Bull Parenter Drug Assoc; 1972 Jun; 26(4):172-81. PubMed ID: 5067998
    [No Abstract] [Full Text] [Related]

  • 34. Fake biotech drugs raise concerns.
    Fox JL.
    Nat Biotechnol; 2001 Jul; 19(7):603. PubMed ID: 11433258
    [No Abstract] [Full Text] [Related]

  • 35. FDA's role in drug product recalls.
    Crawford SY.
    Am J Hosp Pharm; 1991 Dec; 48(12):2595-6. PubMed ID: 1814194
    [No Abstract] [Full Text] [Related]

  • 36. Validation--how much can the world afford? Are we getting value for money?
    Anisfeld MH.
    J Pharm Sci Technol; 1994 Dec; 48(1):45-8. PubMed ID: 8004419
    [Abstract] [Full Text] [Related]

  • 37. The regulation of medicinal products derived from human blood or plasma in the European Community.
    Brunko P.
    Dev Biol Stand; 1993 Dec; 81():269-71. PubMed ID: 8174813
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
    World Health Organization.
    World Health Organ Tech Rep Ser; 2005 Dec; 929():1-142, backcover. PubMed ID: 16353684
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.